The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury

Michael R. Hoane, Jeremy L. Pierce, Michael A. Holland, Nicholas D. Birky, Tan Dang, Michael P. Vitek, Suzanne E. McKenna

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

It has previously been shown that small peptide molecules derived from the apolipoprotein E (ApoE) receptor binding region are anti-inflammatory in nature and can improve outcome following head injury. The present study evaluated the preclinical efficacy of COG1410, a small molecule ApoE-mimetic peptide (1410 daltons), following cortical contusion injury (CCI). Animals were prepared with a unilateral CCI of the sensorimotor cortex (SMC) or sham procedure. Thirty mins post-CCI the animals received i.v. infusions of 0.8 mg/kg COG1410, 0.4 mg/kg COG1410, or vehicle. Starting on day 2, the animals were tested on a battery of behavioral measures to assess sensorimotor (vibrissae-forelimb placing and forelimb use-asymmetry), and motor (tapered balance beam) performance. Administration of the 0.8 mg/kg dose of COG1410 significantly improved recovery on the vibrissae-forelimb and limb asymmetry tests. However, no facilitation was observed on the tapered beam. The low dose (0.4 mg/kg) of COG1410 did not show any significant differences compared to vehicle. Lesion analysis revealed that the 0.8 mg/kg dose of COG1410 significantly reduced the size of the injury cavity compared to the 0.4 mg/kg dose and vehicle. The 0.8 mg/kg dose also reduced the number of glial fibrillary acid protein (GFAP+) reactive cells in the injured cortex. These results suggest that a single dose of COG1410 facilitates behavioral recovery and provides neuroprotection in a dose and task-dependent manner. Thus, the continued clinical development of ApoE based therapeutics is warranted and could represent a novel strategy for the treatment of traumatic brain injuries.

Original languageEnglish (US)
Pages (from-to)1108-1118
Number of pages11
JournalJournal of Neurotrauma
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Apolipoproteins E
Peptides
Wounds and Injuries
Forelimb
Vibrissae
Low Density Lipoprotein Receptor-Related Protein-1
Glial Fibrillary Acidic Protein
Brain Contusion
COG1410
Craniocerebral Trauma
Anti-Inflammatory Agents
Extremities

Keywords

  • ApoE
  • Behavioral recovery
  • GFAP
  • Neuroprotection
  • Recovery of function
  • TBI
  • Trauma

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. / Hoane, Michael R.; Pierce, Jeremy L.; Holland, Michael A.; Birky, Nicholas D.; Dang, Tan; Vitek, Michael P.; McKenna, Suzanne E.

In: Journal of Neurotrauma, Vol. 24, No. 7, 01.07.2007, p. 1108-1118.

Research output: Contribution to journalArticle

Hoane, Michael R. ; Pierce, Jeremy L. ; Holland, Michael A. ; Birky, Nicholas D. ; Dang, Tan ; Vitek, Michael P. ; McKenna, Suzanne E. / The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. In: Journal of Neurotrauma. 2007 ; Vol. 24, No. 7. pp. 1108-1118.
@article{80c1c479c5db4580996cbbe74b73550f,
title = "The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury",
abstract = "It has previously been shown that small peptide molecules derived from the apolipoprotein E (ApoE) receptor binding region are anti-inflammatory in nature and can improve outcome following head injury. The present study evaluated the preclinical efficacy of COG1410, a small molecule ApoE-mimetic peptide (1410 daltons), following cortical contusion injury (CCI). Animals were prepared with a unilateral CCI of the sensorimotor cortex (SMC) or sham procedure. Thirty mins post-CCI the animals received i.v. infusions of 0.8 mg/kg COG1410, 0.4 mg/kg COG1410, or vehicle. Starting on day 2, the animals were tested on a battery of behavioral measures to assess sensorimotor (vibrissae-forelimb placing and forelimb use-asymmetry), and motor (tapered balance beam) performance. Administration of the 0.8 mg/kg dose of COG1410 significantly improved recovery on the vibrissae-forelimb and limb asymmetry tests. However, no facilitation was observed on the tapered beam. The low dose (0.4 mg/kg) of COG1410 did not show any significant differences compared to vehicle. Lesion analysis revealed that the 0.8 mg/kg dose of COG1410 significantly reduced the size of the injury cavity compared to the 0.4 mg/kg dose and vehicle. The 0.8 mg/kg dose also reduced the number of glial fibrillary acid protein (GFAP+) reactive cells in the injured cortex. These results suggest that a single dose of COG1410 facilitates behavioral recovery and provides neuroprotection in a dose and task-dependent manner. Thus, the continued clinical development of ApoE based therapeutics is warranted and could represent a novel strategy for the treatment of traumatic brain injuries.",
keywords = "ApoE, Behavioral recovery, GFAP, Neuroprotection, Recovery of function, TBI, Trauma",
author = "Hoane, {Michael R.} and Pierce, {Jeremy L.} and Holland, {Michael A.} and Birky, {Nicholas D.} and Tan Dang and Vitek, {Michael P.} and McKenna, {Suzanne E.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1089/neu.2006.0254",
language = "English (US)",
volume = "24",
pages = "1108--1118",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury

AU - Hoane, Michael R.

AU - Pierce, Jeremy L.

AU - Holland, Michael A.

AU - Birky, Nicholas D.

AU - Dang, Tan

AU - Vitek, Michael P.

AU - McKenna, Suzanne E.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - It has previously been shown that small peptide molecules derived from the apolipoprotein E (ApoE) receptor binding region are anti-inflammatory in nature and can improve outcome following head injury. The present study evaluated the preclinical efficacy of COG1410, a small molecule ApoE-mimetic peptide (1410 daltons), following cortical contusion injury (CCI). Animals were prepared with a unilateral CCI of the sensorimotor cortex (SMC) or sham procedure. Thirty mins post-CCI the animals received i.v. infusions of 0.8 mg/kg COG1410, 0.4 mg/kg COG1410, or vehicle. Starting on day 2, the animals were tested on a battery of behavioral measures to assess sensorimotor (vibrissae-forelimb placing and forelimb use-asymmetry), and motor (tapered balance beam) performance. Administration of the 0.8 mg/kg dose of COG1410 significantly improved recovery on the vibrissae-forelimb and limb asymmetry tests. However, no facilitation was observed on the tapered beam. The low dose (0.4 mg/kg) of COG1410 did not show any significant differences compared to vehicle. Lesion analysis revealed that the 0.8 mg/kg dose of COG1410 significantly reduced the size of the injury cavity compared to the 0.4 mg/kg dose and vehicle. The 0.8 mg/kg dose also reduced the number of glial fibrillary acid protein (GFAP+) reactive cells in the injured cortex. These results suggest that a single dose of COG1410 facilitates behavioral recovery and provides neuroprotection in a dose and task-dependent manner. Thus, the continued clinical development of ApoE based therapeutics is warranted and could represent a novel strategy for the treatment of traumatic brain injuries.

AB - It has previously been shown that small peptide molecules derived from the apolipoprotein E (ApoE) receptor binding region are anti-inflammatory in nature and can improve outcome following head injury. The present study evaluated the preclinical efficacy of COG1410, a small molecule ApoE-mimetic peptide (1410 daltons), following cortical contusion injury (CCI). Animals were prepared with a unilateral CCI of the sensorimotor cortex (SMC) or sham procedure. Thirty mins post-CCI the animals received i.v. infusions of 0.8 mg/kg COG1410, 0.4 mg/kg COG1410, or vehicle. Starting on day 2, the animals were tested on a battery of behavioral measures to assess sensorimotor (vibrissae-forelimb placing and forelimb use-asymmetry), and motor (tapered balance beam) performance. Administration of the 0.8 mg/kg dose of COG1410 significantly improved recovery on the vibrissae-forelimb and limb asymmetry tests. However, no facilitation was observed on the tapered beam. The low dose (0.4 mg/kg) of COG1410 did not show any significant differences compared to vehicle. Lesion analysis revealed that the 0.8 mg/kg dose of COG1410 significantly reduced the size of the injury cavity compared to the 0.4 mg/kg dose and vehicle. The 0.8 mg/kg dose also reduced the number of glial fibrillary acid protein (GFAP+) reactive cells in the injured cortex. These results suggest that a single dose of COG1410 facilitates behavioral recovery and provides neuroprotection in a dose and task-dependent manner. Thus, the continued clinical development of ApoE based therapeutics is warranted and could represent a novel strategy for the treatment of traumatic brain injuries.

KW - ApoE

KW - Behavioral recovery

KW - GFAP

KW - Neuroprotection

KW - Recovery of function

KW - TBI

KW - Trauma

UR - http://www.scopus.com/inward/record.url?scp=34547104209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547104209&partnerID=8YFLogxK

U2 - 10.1089/neu.2006.0254

DO - 10.1089/neu.2006.0254

M3 - Article

C2 - 17610351

AN - SCOPUS:34547104209

VL - 24

SP - 1108

EP - 1118

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 7

ER -